
Prothena Corporation plc
NASDAQ:PRTA
13.74 (USD) • At close March 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Prothena Corporation plc |
Symbool | PRTA |
Munteenheid | USD |
Prijs | 13.74 |
Beurswaarde | 739,582,980 |
Dividendpercentage | 0% |
52-weken bereik | 11.7 - 26.75 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gene G. Kinney Ph.D. |
Website | https://www.prothena.com |
Over Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)